RxDoctor Payments Data

Timothy Mathis, MD

Family Medicine · Shreveport, LANPI 1730185927

Payments from drug & device makers

$3,267in general payments, 2019–2025

Across 206 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$451
  • Boehringer Ingelheim$338
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$319
  • Merck$291
  • AbbVie$262
  • Amgen$252
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,20398%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,267 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$127,942
Medicare patients
215
Services billed
5,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$74,840
RybelsusSemaglutide63$63,154
TradjentaLinagliptin55$52,739
FarxigaDapagliflozin Propanediol33$35,462
JardianceEmpagliflozin22$20,675
JanuviaSitagliptin Phosphate19$17,992
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$13,678
Telmisartan195$6,184
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,765
Atorvastatin Calcium341$3,399
Eszopiclone12$3,271
Indapamide207$2,812
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,347
Felodipine ErFelodipine56$1,960
Metoprolol Succinate99$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$451$137,995120 claims
Boehringer IngelheimTradjenta, Jardiance$338$73,41477 claims
AstraZenecaFarxiga$242$35,46233 claims
MerckJanuvia$291$17,99219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →